Share Twitter LinkedIn Facebook Email Brian I. Rini, MD, Cleveland Clinic explains PR Results IMmotion151 Study | Progression-Free Survival & Encouraging Signals at Annual Meeting 2018
Tivozanib for RCC: Unpacking Efficacy, Safety, and Dose Optimization – Bradley McGregor, MD – Dana Farber Genitourinary 3 Mins Read
Renal Cell Carcinoma TiNivo-2 Study: Patient-Reported Outcomes in Treatment Post-ICI Kidney 3 Mins Read
VIDEO: FDA Approves Atezolizumab / Tecentriq Hybreza For Subcutaneous PD-(L)1 Cancer Immunotherapy in NSCLC Kidney 4 Mins Read